NewAmsterdam Pharma Company N.V. Foreign Currency Transaction Gain (Loss), before Tax
NewAmsterdam Pharma Company N.V. (NAMS) reported Foreign Currency Transaction Gain (Loss), before Tax of -$526.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$526.00K, a 106.10% decline year-over-year.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$1.61M, a 137.57% decline year-over-year.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$82.00K.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $218.00K, a 95.34% decline year-over-year.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for fiscal 2025 was $13.05M.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$6.60M, a 230.45% decline from fiscal 2023.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for fiscal 2023 was $5.06M.
- NewAmsterdam Pharma Company N.V. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$9.75M, a 671.34% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$526.00K 10-Q · filed 2026-08-05 | -$2.14M 10-Q · filed 2026-08-05 | -$2.22M derived: sum of 3 quarters · filed 2026-08-05 | -$2.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.61M 10-Q · filed 2026-05-07 | -$1.70M derived: sum of 2 quarters · filed 2026-05-07 | -$1.48M derived: sum of 3 quarters · filed 2026-05-07 | $7.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $136.00K derived: sum of 2 quarters · filed 2026-02-18 | $8.76M derived: sum of 3 quarters · filed 2026-08-05 | $13.05M 10-K · filed 2026-02-18 |
| 2025-09-30 | $218.00K 10-Q · filed 2025-11-05 | $8.84M derived: sum of 2 quarters · filed 2026-08-05 | $13.14M 10-Q · filed 2025-11-05 | $5.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.63M 10-Q · filed 2026-08-05 | $12.92M 10-Q · filed 2026-08-05 | $5.05M derived: sum of 3 quarters · filed 2026-08-05 | $9.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.29M 10-Q · filed 2026-05-07 | -$3.58M derived: sum of 2 quarters · filed 2026-05-07 | $1.11M derived: sum of 3 quarters · filed 2026-05-07 | $113.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$3.19M derived: sum of 2 quarters · filed 2026-02-18 | -$4.18M derived: sum of 3 quarters · filed 2026-02-18 | -$6.60M 10-K · filed 2026-02-18 |
| 2024-09-30 | $4.68M 10-Q · filed 2025-11-05 | $3.69M derived: sum of 2 quarters · filed 2025-11-05 | $1.27M 10-Q · filed 2025-11-05 | $6.49M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | -$994.00K 10-Q · filed 2025-08-06 | -$3.41M 10-Q · filed 2025-08-06 | $1.81M derived: sum of 3 quarters · filed 2026-02-18 | -$1.35M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | -$2.42M 10-Q · filed 2025-05-08 | $2.80M derived: sum of 2 quarters · filed 2026-02-18 | -$355.00K derived: sum of 3 quarters · filed 2026-02-18 | -$427.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $2.06M derived: sum of 2 quarters · filed 2026-02-18 | $1.99M derived: sum of 3 quarters · filed 2026-02-18 | $5.06M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$3.15M 10-Q · filed 2024-11-06 | -$3.23M derived: sum of 2 quarters · filed 2024-11-06 | -$160.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$72.00K 10-Q · filed 2024-08-07 | $3.00M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $3.07M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$9.75M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $1.71M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |